[HTML][HTML] Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review
ME Lacouture, M Anadkat, A Jatoi, T Garawin… - Clinical colorectal …, 2018 - Elsevier
Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been
shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without …
shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without …
Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer
MC Annunziata, A De Stefano, G Fabbrocini… - Clinical Drug …, 2019 - Springer
The use of targeted therapies, when added to conventional chemotherapy, has significantly
improved clinical outcomes and survival of cancer patients. While targeted therapies do not …
improved clinical outcomes and survival of cancer patients. While targeted therapies do not …
Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer
J Ouwerkerk, C Boers-Doets - European Journal of Oncology Nursing, 2010 - Elsevier
PURPOSE: To provide oncology nurses with an overview of the toxicity management
associated with the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies …
associated with the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies …
Management and grading of EGFR inhibitor-induced cutaneous toxicity
J Beech, T Germetaki, M Judge, N Paton… - Future …, 2018 - Taylor & Francis
Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on
patient treatment continuation, quality of life and healthcare resource utilization. This paper …
patient treatment continuation, quality of life and healthcare resource utilization. This paper …
Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of …
D Cui, D Cao, Y Yang, M Qiu, Y Huang, C Yi - Molecular biology reports, 2014 - Springer
Anti-EGFR monoclonal antibodies (anti-EGFR MoAbs) in metastatic colorectal cancer
(mCRC) treatment are still not effective in all patients. This study aimed to evaluate the …
(mCRC) treatment are still not effective in all patients. This study aimed to evaluate the …
[HTML][HTML] Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
Background Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor
(EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral …
(EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral …
Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer: Meta‐analytical estimation and …
BACKGROUND: Antiepidermal growth factor receptor (anti‐EGFR) monoclonal antibodies
(MoAbs) are indicated for the treatment of metastatic colorectal cancer patients, but some …
(MoAbs) are indicated for the treatment of metastatic colorectal cancer patients, but some …
[HTML][HTML] Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
B Melosky, R Burkes, D Rayson, T Alcindor… - Current …, 2009 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (egfr) is often overexpressed or dysregulated in a
variety of solid tumours, including gastrointestinal (gi) malignancies. Agents targeting the …
variety of solid tumours, including gastrointestinal (gi) malignancies. Agents targeting the …
[HTML][HTML] Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer …
A Rowland, MM Dias, MD Wiese… - European Journal of …, 2016 - Elsevier
Background Metastatic colorectal cancer (mCRC) tumours harbouring a RAS mutation are
associated with a lack of treatment benefit from anti-EGFR monoclonal antibodies (mAbs) …
associated with a lack of treatment benefit from anti-EGFR monoclonal antibodies (mAbs) …
Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis
D Rossini, MM Germani, F Pagani, A Pellino… - Clinical Colorectal …, 2020 - Elsevier
Background On the basis of retrospective analyses and phase 2 studies, metastatic
colorectal cancer patients whose disease responded to a first-line regimen containing an …
colorectal cancer patients whose disease responded to a first-line regimen containing an …